Palexia Retard (Tapentadol Hydrochloride)

Tapentadol, the active ingredient in Palexia Retard, is an opioid analgesic presented as a prolonged‑release formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when other treatments are inadequate. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tapentadol Retard acts on the central nervous system to relieve pain associated with several chronic conditions. - Chronic low back pain: provides long‑lasting analgesia for patients with persistent lumbar discomfort. - Osteoarthritis pain: reduces pain intensity and improves functional ability in affected joints. - Neuropathic pain associated with diabetic peripheral neuropathy: alleviates burning and shooting sensations. - Cancer‑related chronic pain: contributes to overall pain control as part of a multimodal regimen.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Dizziness: sensation of light‑headedness. - Somnolence: increased sleepiness. - Headache: mild cranial discomfort. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening. - Seizures: convulsive episodes, particularly at high doses. - Severe hypotension: marked drop in blood pressure. - Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities when combined with serotonergic agents. - Dependence or abuse potential: risk of misuse with prolonged use. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Assess renal function: adjust use in severe impairment. - Assess hepatic function: caution in liver disease. - Evaluate for respiratory disorders: avoid in uncontrolled sleep‑apnea. - Review concomitant CNS depressants: increased sedation risk. - Monitor for signs of abuse: implement risk‑mitigation strategies. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Tapentadol may interact with several drug classes, requiring careful review of a patient’s medication list.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome. - CNS depressants (benzodiazepines, barbiturates): profound sedation and respiratory depression. - Serotonergic agents (SSRIs, SNRIs, tramadol): heightened serotonin syndrome risk.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (quinidine, fluoxetine): may increase tapentadol plasma levels. - CYP3A4 inducers (rifampicin, carbamazepine): may reduce analgesic effect. - Antihypertensives: additive hypotensive effect. - Alcohol: enhanced central nervous system depression.